Identification of host factors and compounds to boost viral transduction
AssigneeUniversity of Massachusetts
InventorsJun Xie, Guangping Gao, Jisun Lee
Life of this patent
Estimating the term…
Abstract
Provided herein are a) pharmaceutical compositions comprising a vector, a host protein inhibitor, and a pharmaceutically acceptable carrier; b) methods of delivering a transgene to a cell in a subject, said method comprising administering to the subject a pharmaceutical composition comprising a vector and a host protein inhibitor; c) methods of increasing transduction efficiency of a vector to a cell, said method comprising contacting the cell with a host protein inhibitor; and d) methods of treating a disease in a subject, wherein the method comprises administering to the subject in need thereof a pharmaceutical composition comprising a vector and a host protein inhibitor.
Claims34
A pharmaceutical composition comprising a vector, a host protein inhibitor or a stereoisomer, tautomer or salt thereof, and a pharmaceutically acceptable carrier, wherein the host protein is eIF4A1, eIF4A2, eIF4A3, RAP1A, NIFK, SART1, PLS1, or SF3B6, and wherein the vector comprises a transgene operably linked to regulatory sequences which direct expression of a product from the transgene in a cell.
A method of delivering a transgene to a cell in a subject, said method comprising administering to the subject a pharmaceutical composition comprising a vector and a host protein inhibitor or a stereoisomer, tautomer or salt thereof, wherein the host protein is eIF4A1, eIF4A2, eIF4A3, RAP1A, NIFK, SART1, PLS1, or SF3B6, and wherein the vector comprises the transgene operably linked to regulatory sequences which direct expression of a product from the transgene in the cell.
A method of increasing transduction efficiency of a vector in a cell, said method comprising contacting the cell with a host protein inhibitor or a stereoisomer, tautomer or salt thereof, wherein the host protein is eIF4A1, eIF4A2, eIF4A3, RAP1A, NIFK, SART1, PLS1, or SF3B6, and wherein the vector comprises a transgene operably linked to regulatory sequences which direct expression of a product from the transgene in the cell.
A method of treating a disease in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising a vector and a host protein inhibitor or a stereoisomer, tautomer or salt thereof, wherein the host protein is eIF4A1, eIF4A2, eIF4A3, RAP1A, NIFK, SART1, PLS1, or SF3B6, and wherein the vector comprises a transgene operably linked to regulatory sequences which direct expression of a product from the transgene in a cell.
Dependencies are inferred from the claim text.